Cohort study
Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein
- Prospective cohort study
- Copenhagen General Population Study
- multivariable-adjusted
Authors' conclusion
High lipoprotein(a) was a main driver for the risk of ASCVD, myocardial infarction, and aortic valve stenosis independent of C-reactive protein levels.
Study context
- Population
- General population, Copenhagen General Population Study
- Participants
- 68,090 participants
- Exposure
- Lp 91st–100th vs 1st–33rd percentiles, by CRP <2 vs ≥2 mg/l
- Outcome
- ASCVD, MI and aortic valve stenosis by lipoprotein(a), irrespective of C-reactive protein
- Follow-up
- Median 8.1 years
Main finding
As reported in the abstract
91st-100th percentiles vs 1st-33rd percentilesHazard ratio (95% CI)
ASCVD, CRP <2 mg/l
1.61(1.43–1.81)
ASCVD, CRP ≥2 mg/l
1.57(1.36–1.82)
MI, CRP <2 mg/l
2.08(1.76–2.45)
MI, CRP ≥2 mg/l
1.65(1.34–2.04)
aortic valve stenosis, CRP <2 mg/l
2.01(1.59–2.55)
aortic valve stenosis, CRP ≥2 mg/l
1.73(1.31–2.27)
Observational data: associations, not effects.
Further findings
Events during follow-up · median follow-up 8.1 years
- Atherosclerotic cardiovascular disease (ASCVD)
- 5104
- MI
- 2432
- Aortic valve stenosis
- 1220
Highest absolute 10-year risk (age 70-79 years, Lp(a) 91st-100th percentiles, CRP ≥2 mg/l)
- Men, ASCVD
- 34%
- Men, MI
- 19%
- Men, aortic valve stenosis
- 13%
- Women, ASCVD
- 20%
- Women, MI
- 10%
- Women, aortic valve stenosis
- 8%
Original publication
Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Eur Heart J. Published 21 February 2023. doi:10.1093/eurheartj/ehad055
Summarised from the published abstract; every number is checked against it